Correlation Between Unicycive Therapeutics and Keros Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Keros Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Keros Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and Keros Therapeutics, you can compare the effects of market volatilities on Unicycive Therapeutics and Keros Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Keros Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Keros Therapeutics.

Diversification Opportunities for Unicycive Therapeutics and Keros Therapeutics

0.29

Correlation Coefficient

Unicycive Therapeutics  Keros Therapeutics

Modest diversification

The 3 months correlation between Unicycive and Keros is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Keros Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Keros Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Keros Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Keros Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Keros Therapeutics go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Keros Therapeutics

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 0.49 times more return on investment than Keros Therapeutics. However, Unicycive Therapeutics is 2.02 times less risky than Keros Therapeutics. It trades about -0.07 of its potential returns per unit of risk. Keros Therapeutics is currently generating about -0.16 per unit of risk. If you would invest  74.00  in Unicycive Therapeutics on December 2, 2024 and sell it today you would lose (19.00) from holding Unicycive Therapeutics or give up 25.68% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Unicycive Therapeutics  vs.  Keros Therapeutics

Unicycive Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Unicycive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Keros Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Keros Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Unicycive Therapeutics and Keros Therapeutics

The main advantage of trading using opposite Unicycive Therapeutics and Keros Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Keros Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros Therapeutics will offset losses from the drop in Keros Therapeutics' long position.

The idea behind Unicycive Therapeutics and Keros Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.